Real-time monitoring of tumorigenesis, dissemination, & drug response in a preclinical model of lymphangioleiomyomatosis/tuberous sclerosis complex

PLoS ONE

Volumn 7, Issue 6, 2012, Pages

  Liu, Fangbing ^a   Lunsford, Elaine P ^a   Tong, Jingli ^a   Ashitate, Yoshitomo ^a   Gibbs, Summer L ^a   Yu, Jane ^b   Choi, Hak Soo ^a   Henske, Elizabeth P ^b   Frangioni, John V ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; GREEN FLUORESCENT PROTEIN; PERTECHNETIC ACID TC 99M; RAPAMYCIN; SODIUM IODIDE SYMPORTER;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CARCINOGENESIS; CELL PROLIFERATION; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE MICROSCOPY; IMMUNOHISTOCHEMISTRY; IN VITRO GENE TRANSFER; IN VIVO GENE TRANSFER; LUNG NODULE; LYMPH NODE METASTASIS; LYMPHANGIOLEIOMYOMATOSIS; MALE; MOUSE; NONHUMAN; PATHOGENESIS; PROTEIN EXPRESSION; SEX DIFFERENCE; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SUPPRESSOR GENE; TUBEROUS SCLEROSIS; TUBEROUS SCLEROSIS COMPLEX 2 GENE; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CELL TRANSFORMATION, NEOPLASTIC; DISEASE MODELS, ANIMAL; GREEN FLUORESCENT PROTEINS; HUMANS; LYMPHANGIOLEIOMYOMATOSIS; MICE; MICE, NUDE; MICROSCOPY, FLUORESCENCE; MONITORING, PHYSIOLOGIC; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TOMOGRAPHY, X-RAY COMPUTED; TUBEROUS SCLEROSIS; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEINS;

EID: 84862502329     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0038589     Document Type: Article

References (49)

1. Crino PB, Nathanson KL, Henske EP, (2006) The tuberous sclerosis complex. N Engl J Med 355: 1345-1356.
2. Juvet SC, McCormack FX, Kwiatkowski DJ, Downey GP, (2007) Molecular pathogenesis of lymphangioleiomyomatosis: lessons learned from orphans. Am J Respir Cell Mol Biol 36: 398-408.
3. Franz DN, Bissler JJ, McCormack FX, (2010) Tuberous sclerosis complex: neurological, renal and pulmonary manifestations. Neuropediatric 41: 199-208.
4. Moss J, Avila NA, Barnes PM, Litzenberger RA, Bechtle J, et al. (2001) Prevalence and clinical characteristics of lymphangioleiomyomatosis (LAM) in patients with tuberous sclerosis complex. Am J Respir Crit Care Med 164: 669-671.
5. Glasgow CG, Taveira-Dasilva AM, Darling TN, Moss J, (2008) Lymphatic involvement in lymphangioleiomyomatosis. Ann N Y Acad Sci 1131: 206-214.
6. Nurok M, Eslick I, Carvalho CR, Costabel U, D'Armiento J, et al. (2010) The International LAM Registry: a component of an innovative web-based clinician, researcher, and patient-driven rare disease research platform. Lymphat Res Biol 8: 81-87.
7. Smolarek TA, Wessner LL, McCormack FX, Mylet JC, Menon AG, et al. (1998) Evidence that lymphangiomyomatosis is caused by TSC2 mutations: chromosome 16p13 loss of heterozygosity in angiomyolipomas and lymph nodes from women with lymphangiomyomatosis. Am J Hum Genet 62: 810-815.
8. Carsillo T, Astrinidis A, Henske EP, (2000) Mutations in the tuberous sclerosis complex gene TSC2 are a cause of sporadic pulmonary lymphangioleiomyomatosis. Proc Natl Acad Sci U S A 97: 6085-6090.
9. Strizheva GD, Carsillo T, Kruger WD, Sullivan EJ, Ryu JH, et al. (2001) The spectrum of mutations in TSC1 and TSC2 in women with tuberous sclerosis and lymphangiomyomatosis. Am J Respir Crit Care Med 163: 253-258.
10. Tee AR, Fingar DC, Manning BD, Kwiatkowski DJ, Cantley LC, et al. (2002) Tuberous sclerosis complex-1 and-2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling. Proc Natl Acad Sci U S A 99: 13571-13576.
11. Krymskaya VP, (2003) Tumour suppressors hamartin and tuberin: intracellular signalling. Cell Signal 15: 729-739.
12. Fingar DC, Salama S, Tsou C, Harlow E, Blenis J, (2002) Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1/eIF4E. Genes Dev 16: 1472-1487.
13. Aoki M, Blazek E, Vogt PK, (2001) A role of the kinase mTOR in cellular transformation induced by the oncoproteins P3k and Akt. Proc Natl Acad Sci U S A 98: 136-141.
14. Shaw RJ, Cantley LC, (2006) Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 441: 424-430.
15. Choo AY, Kim SG, Vander Heiden MG, Mahoney SJ, Vu H, et al. (2010) Glucose addiction of TSC null cells is caused by failed mTORC1-dependent balancing of metabolic demand with supply. Mol Cell 38: 487-499.
16. Knudson AG Jr, (1971) Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci U S A 68: 820-823.
17. Knudson AG, (1996) Hereditary cancer: two hits revisited. J Cancer Res Clin Oncol 122: 135-140.
18. Zhe X, Schuger L, (2004) Combined smooth muscle and melanocytic differentiation in lymphangioleiomyomatosis. J Histochem Cytochem 52: 1537-1542.
19. Henske EP, (2003) Metastasis of benign tumor cells in tuberous sclerosis complex. Genes Chromosomes Cancer 38: 376-381.
20. Astrinidis A, Henske EP, (2005) Tuberous sclerosis complex: linking growth and energy signaling pathways with human disease. Oncogene 24: 7475-7481.
21. Goncharova EA, Goncharov DA, Lim PN, Noonan D, Krymskaya VP, (2006) Modulation of cell migration and invasiveness by tumor suppressor TSC2 in lymphangioleiomyomatosis. Am J Respir Cell Mol Biol 34: 473-480.
22. Arbiser JL, Yeung R, Weiss SW, Arbiser ZK, Amin MB, et al. (2001) The generation and characterization of a cell line derived from a sporadic renal angiomyolipoma: use of telomerase to obtain stable populations of cells from benign neoplasms. Am J Pathol 159: 483-491.
23. Lesma E, Grande V, Carelli S, Brancaccio D, Canevini MP, et al. (2005) Isolation and growth of smooth muscle-like cells derived from tuberous sclerosis complex-2 human renal angiomyolipoma: epidermal growth factor is the required growth factor. Am J Pathol 167: 1093-1103.
24. Lesma E, Sirchia SM, Ancona S, Carelli S, Bosari S, et al. (2009) The methylation of the TSC2 promoter underlies the abnormal growth of TSC2 angiomyolipoma-derived smooth muscle cells. Am J Pathol 174: 2150-2159.
25. Darling TN, Pacheco-Rodriguez G, Gorio A, Lesma E, Walker C, et al. (2010) Lymphangioleiomyomatosis and TSC2-/- cells. Lymphat Res Biol 8: 59-69.
26. Lacroix L, Mian C, Caillou B, Talbot M, Filetti S, et al. (2001) Na(+)/I(-) symporter and Pendred syndrome gene and protein expressions in human extra-thyroidal tissues. Eur J Endocrinol 144: 297-302.
27. Vayre L, Sabourin JC, Caillou B, Ducreux M, Schlumberger M, et al. (1999) Immunohistochemical analysis of Na+/I- symporter distribution in human extra-thyroidal tissues. Eur J Endocrinol 141: 382-386.
28. Dadachova E, Carrasco N, (2004) The Na/I symporter (NIS): imaging and therapeutic applications. Semin Nucl Med 34: 23-31.
29. Marsee DK, Shen DH, MacDonald LR, Vadysirisack DD, Lin X, et al. (2004) Imaging of metastatic pulmonary tumors following NIS gene transfer using single photon emission computed tomography. Cancer Gene Ther 11: 121-127.
30. Yu J, Astrinidis A, Howard S, Henske EP, (2004) Estradiol and tamoxifen stimulate LAM-associated angiomyolipoma cell growth and activate both genomic and nongenomic signaling pathways. Am J Physiol Lung Cell Mol Physiol 286: L694-700.
31. Hong F, Larrea MD, Doughty C, Kwiatkowski DJ, Squillace R, et al. (2008) mTOR-raptor binds and activates SGK1 to regulate p27 phosphorylation. Mol Cell 30: 701-711.
32. Woodrum C, Nobil A, Dabora SL, (2010) Comparison of three rapamycin dosing schedules in A/J Tsc2+/- mice and improved survival with angiogenesis inhibitor or asparaginase treatment in mice with subcutaneous tuberous sclerosis related tumors. J Transl Med 8: 14.
33. Capron F, Ameille J, Leclerc P, Mornet P, Barbagellata M, et al. (1983) Pulmonary lymphangioleiomyomatosis and Bourneville's tuberous sclerosis with pulmonary involvement: the same disease? Cancer 52: 851-855.
34. Cornog JL Jr, Enterline HT, (1966) Lymphangiomyoma, a benign lesion of chyliferous lymphatics synonymous with lymphangiopericytoma. Cancer 19: 1909-1930.
35. El-Hashemite N, Walker V, Kwiatkowski DJ, (2005) Estrogen enhances whereas tamoxifen retards development of Tsc mouse liver hemangioma: a tumor related to renal angiomyolipoma and pulmonary lymphangioleiomyomatosis. Cancer Res 65: 2474-2481.
36. Finlay GA, Malhowski AJ, Polizzi K, Malinowska-Kolodziej I, Kwiatkowski DJ, (2009) Renal and liver tumors in Tsc2(+/-) mice, a model of tuberous sclerosis complex, do not respond to treatment with atorvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Mol Cancer Ther 8: 1799-1807.
37. Wlodarski PK, Maksym R, Oldak M, Jozwiak S, Wojcik A, et al. (2008) Tuberin-heterozygous cell line TSC2ang1 as a model for tuberous sclerosis-associated skin lesions. Int J Mol Med 21: 245-250.
38. Kwiatkowski DJ, (2010) Animal models of lymphangioleiomyomatosis (LAM) and tuberous sclerosis complex (TSC). Lymphat Res Biol 8: 51-57.
39. Lesma E, Grande V, Ancona S, Carelli S, Di Giulio AM, et al. (2008) Anti-EGFR antibody efficiently and specifically inhibits human TSC2-/- smooth muscle cell proliferation. Possible treatment options for TSC and LAM. PLoS One 3: e3558.
40. Walker CL, Hunter D, Everitt JI, (2003) Uterine leiomyoma in the Eker rat: a unique model for important diseases of women. Genes Chromosomes Cancer 38: 349-356.
41. Yu JJ, Robb VA, Morrison TA, Ariazi EA, Karbowniczek M, et al. (2009) Estrogen promotes the survival and pulmonary metastasis of tuberin-null cells. Proc Natl Acad Sci U S A 106: 2635-2640.
42. Crawford HC, Matrisian LM (1994-1995) Tumor and stromal expression of matrix metalloproteinases and their role in tumor progression. Invasion Metastasis 14: 234-245.
43. Matsui K, Takeda K, Yu ZX, Travis WD, Moss J, et al. (2000) Role for activation of matrix metalloproteinases in the pathogenesis of pulmonary lymphangioleiomyomatosis. Arch Pathol Lab Med 124: 267-275.
44. Stacker SA, Achen MG, Jussila L, Baldwin ME, Alitalo K, (2002) Lymphangiogenesis and cancer metastasis. Nat Rev Cancer 2: 573-583.
45. Stacker SA, Caesar C, Baldwin ME, Thornton GE, Williams RA, et al. (2001) VEGF-D promotes the metastatic spread of tumor cells via the lymphatics. Nat Med 7: 186-191.
46. Yu J, Henske EP, (2010) mTOR activation, lymphangiogenesis, and estrogen-mediated cell survival: the "perfect storm" of pro-metastatic factors in LAM pathogenesis. Lymphat Res Biol 8: 43-49.
47. Krueger DA, Care MM, Holland K, Agricola K, Tudor C, et al. (2010) Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. N Engl J Med 363: 1801-1811.
48. Bissler JJ, McCormack FX, Young LR, Elwing JM, Chuck G, et al. (2008) Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med 358: 140-151.
49. McCormack FX, Inoue Y, Moss J, Singer LG, Strange C, et al. (2011) Efficacy and safety of sirolimus in lymphangioleiomyomatosis. N Engl J Med 364: 1595-1606.